Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499987 | 0.91 | MRGPRX4 (0.50) | PPARGLMNAALOX5AP | |
| SCHEMBL6500991 | 0.91 | ALOX5AP (0.42) | PPARGALOX5APOPRL1TP53SMN1; SMN2 | |
| SCHEMBL6488244 | 0.87 | LMNA (0.40) | PPARGLMNAALOX5APTP53SMN1; SMN2 | |
| SCHEMBL6491428 | 0.82 | BCL2 (0.46) | PPARGALOX5APTP53MAPT | |
| SCHEMBL7196721 | 0.82 | PPARG (0.46) | PPARGLMNAALOX5APTP53 | |
| SCHEMBL6499570 | 0.81 | BCL2 (0.42) | ALOX5APTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL6490693 | 0.81 | MRGPRX4 (0.43) | LMNAALOX5APOPRL1MAPTNPSR1 | |
| SCHEMBL6488597 | 0.81 | BCL2 (0.50) | PPARGALOX5AP | |
| SCHEMBL6489317 | 0.80 | MTNR1A (0.42) | PPARGLMNAALOX5APSMN1; SMN2MAPT | |
| SCHEMBL6498329 | 0.79 | MAPT (0.41) | PPARGALOX5APTP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885LMNA 3711/4885ALOX5AP 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.